Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and GVAX in high-risk localized prostate cancer
NCT00577356Phase 2Terminated
- Sponsor
- Benaroya Research Institute
- Start
- Feb 2008
- Primary completion
- Sep 2008
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of GVAX pancreatic cancer vaccine in prostate cancer (PCa), sponsored by Benaroya Research Institute. Started Feb 2008; status: terminated.
02
Drugs
GVAX pancreatic cancer vaccine
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00577356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00577356.